In JAMS arbitration, CRA was retained by the Claimant regarding a dispute involving the breach of fiduciary duty by former employees of a clinical stage therapeutic company. CRA estimated the Claimant’s cash flows using contemporaneous Claimant’s financial data, colorectal cancer incidence rates and treatment prices, relevant clinical trial and generic market entry studies, and potentially comparable companies financials. Such information, along with qualitative information, was considered to estimate the Claimant’s risk-adjusted net present value. Claimant presented our valuation methodology and work product in its mediation, which CRA attended.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...